Mucin 1 is a potential therapeutic target in cutaneous T-cell
lymphoma
by Salvia Jain, Dina Stroopinsky, Li Yin, Jacalyn Rosenblatt, Maroof Alam, Parul
Bhargava, Rachael A. Clark, Thomas S. Kupper, Kristen Palmer, Maxwell D. Coll,
Hasan Rajabi, Athalia Pyzer, Michal Bar-Natan, Katarina Luptakova, Jon Arnason,
Robin Joyce, Donald Kufe, and David Avigan
Blood
Volume 126(3):354-362
July 16, 2015
©2015 by American Society of Hematology
Selective expression of MUC1 in CTCL cells.
Salvia Jain et al. Blood 2015;126:354-362
©2015 by American Society of Hematology
Selective expression of MUC1 in CTCL patients.
Salvia Jain et al. Blood 2015;126:354-362
©2015 by American Society of Hematology
GO-203 increases hydrogen peroxide (H2O2) levels in CTCL cells, which is abrogated by
addition of N acetyl cysteine (NAC).
Salvia Jain et al. Blood 2015;126:354-362
©2015 by American Society of Hematology
TIGAR expression is decreased by MUC1 inhibition via ROS. (A-B) HuT-78 and H9 cells were left
untreated and treated with 5 μM GO-203 or 5 μM CP-2 each day for 3 days.
Salvia Jain et al. Blood 2015;126:354-362
©2015 by American Society of Hematology
GO-203 treatment decreases NADPH and GSH levels.
Salvia Jain et al. Blood 2015;126:354-362
©2015 by American Society of Hematology
MUC1-C inhibitor GO-203 is cytotoxic in CTCL cells.
Salvia Jain et al. Blood 2015;126:354-362
©2015 by American Society of Hematology
MUC1-C inhibitor GO-203 is cytotoxic in CTCL primary cells at 48 and 72 hours.
Salvia Jain et al. Blood 2015;126:354-362
©2015 by American Society of Hematology